IN THE CLAIMS

Please cancel claims 11 and 14.

Please amend claims 1 and 2 as indicated below.

The pending claims are believed to be as follows:

1. (Currently amended) A pharmaceutical composition comprising:

a single crystal of a pharmaceutically-acceptable crystal lattice component;

and

an active pharmaceutical ingredient different from and included within the crystal

in a growth-sector specific orientation, the crystal lattice component and the active

pharmaceutical ingredient being pharmaceutically pure;

wherein said crystal lattice component consists essentially of lactose.

2. (Currently amended) A pharmaceutical material comprising:

a mixture of single crystals, each crystal comprising a pharmaceutically-

acceptable crystal lattice component and an active pharmaceutical ingredient different

from and included within the crystal in a growth-sector specific orientation, the crystal

lattice component and the active pharmaceutical ingredient being pharmaceutically pure;

wherein said crystal lattice component consists essentially of lactose.

3. (Original) The pharmaceutical material of claim 2 in which the

crystals comprise at least two crystal lattice components, the first crystal lattice

component being characterized by first pharmacokinetics and the second crystal lattice

component being characterized by second pharmacokinetics.

4. (Original) The pharmaceutical material of claim 2 in which said

mixture comprises a mixture of two different types of said crystals, the first type of the

crystals comprising a first crystal lattice component and the second type of the crystals

comprising at least one crystal lattice component different from the first crystal lattice

component.

5. (Previously amended) The pharmaceutical material of claim 2 in which

the active pharmaceutical ingredient comprises discrete units and the units are included

within the crystals in isolation from one another.

2

- 6. (Previously amended) The pharmaceutical material of claim 2 in which the active pharmaceutical ingredient is included within the crystal at a concentration of about 0.001 to 1 weight percent based on the weight of the crystal including the active pharmaceutical ingredient.
 - 7-10. (previously withdrawn)
 - 11. cancelled
- 12. (Previously amended) The invention of claim 1 and further comprising a pharmaceutically-acceptable adjuvant selected from the group consisting of excipients, diluents, carriers and mixtures thereof.
- 13. (Previously amended) The invention of claim 1 in which the active pharmaceutical ingredient is a biopharmaceutical.
 - 14. cancelled